Normalcy of diet (supplemental nutrition: TPN, PEG, nasogastric tube or IV hydration) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in normalcy of diet (supplemental nutrition: TPN, PEG, nasogastric tube… compared with placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Adults receiving chemotherapy alone for colorectal cancer
Transforming growth factor-beta(2) (TGF-beta2) showed no clear difference in oral mucositis (any severity) compared with placebo; GRADE not reported.
1 finding from 1 review
Overall survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine (intravenous) showed no clear difference in overall survival compared with amifostine (subcutaneous); GRADE not reported.
1 finding from 1 review
HR 1.36 [0.89, 2.10]
1 study
GRADE not reported
Allergic adverse events · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine 200 mg/m2 three times weekly showed no clear difference in allergic response (adverse effect) compared with amifostine 200 mg/m2 five times weekly; GRADE not reported.
1 finding from 1 review
Oral mucositis (moderate to severe) · Adults with cancer receiving treatment
It is very uncertain whether granulocyte-macrophage colony-stimulating factor (GM-CSF) changes oral mucositis (moderate to severe) compared with placebo or no treatment (very low certainty).
2 findings from 1 review
Oral pain · Adults with cancer receiving treatment
Granulocyte-macrophage colony-stimulating factor (GM-CSF) showed no clear difference in oral pain (mean pain score, 0 to 10 scale) compared with placebo or no treatment; GRADE not reported.
1 finding from 1 review
Interruptions to cancer treatment (chemotherapy delays/discontinuations) · Adults with cancer receiving treatment
Keratinocyte growth factor (KGF; palifermin or repifermin),… showed no clear difference in interruptions to cancer treatment (chemotherapy… compared with placebo; GRADE not reported.
1 finding from 1 review
Asthenia · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine showed no clear difference in asthenia (adverse effect) compared with no treatment/placebo; GRADE not reported.
1 finding from 1 review
Oral mucositis (any severity) · Adults receiving chemotherapy alone for colorectal cancer
Intestinal trefoil factor (ITF), oral spray led to lower oral mucositis (any severity) compared with placebo; GRADE not reported.
1 finding from 1 review
Xerostomia (other Chinese medicines) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Overall survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
It is very uncertain whether pilocarpine changes overall survival compared with no treatment/placebo (very low certainty).
1 finding from 1 review
Adverse events · Adults receiving chemotherapy alone for colorectal cancer
1 finding from 1 review
Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Overall survival · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Other oral related symptoms (oral discomfort, eating difficulty, mucosal pain, oral complications) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Quality of life · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
The review found no eligible studies for this question.
1 finding from 1 review
Salivary flow rate (stimulated) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Bethanechol led to higher salivary flow rate (stimulated, ml/min) compared with artificial saliva; GRADE not reported.
2 findings from 1 review
Adverse events · Adults with cancer receiving treatment
1 finding from 1 review
Side effects · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
1 finding from 1 review
Xerostomia (grade >= 2, 0-4 scale) · Patients receiving radiotherapy on its own or in addition to chemotherapy to the head and neck region
Amifostine (intravenous) led to lower xerostomia (grade >= 2, 0-4 scale) compared with amifostine (subcutaneous); GRADE not reported.
2 findings from 1 review